Advanced conventional chondrosarcomas: Time to revisit treatments and clinical research for what is not an indolent disease

Authors

  • Antoine Italiano MD, PhD

    Corresponding author
    1. Department of Medical Oncology, Bergonié Institute, Bordeaux, France
    • Corresponding author: Antoine Italiano, MD, PhD, Institut Bergonié, Department of Medical Oncology, 229 cours de l'Argonne, 33076 Bordeaux Cedex, France; Fax: (011) 33 05 56 33 33 83; a.italiano@bordequx.unicancer.fr

    Search for more papers by this author

  • See referenced original article on pages 3159–64, this issue.

Abstract

Medical and surgical oncologists involved in the management of patients with sarcoma know well that the management of those with recurrent chondrosarcoma is quite challenging. In light of the currently available data, anthracycline-based chemotherapy and radiotherapy represent reasonable options for chondrosarcoma patients not eligible to a clinical trial with good performance status and who have unresectable metastatic or locally advanced disease, respectively.

Ancillary